Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31519330 | 1.00 | CYP2A6 (0.49) | CYP2A6KIF11EGFRALDH1A1KDM4E | |
| SCHEMBL16030171 | 0.88 | CYP2A6 (0.47) | CYP2A6KIF11EGFRALDH1A1KDM4E | |
| SCHEMBL30406251 | 0.88 | CYP2A6 (0.47) | CYP2A6KIF11EGFRALDH1A1KDM4E | |
| SCHEMBL22926278 | 0.79 | EGFR (0.38) | CYP2A6KIF11EGFRPTGS2 | |
| SCHEMBL4073976 | 0.74 | CYP2A6 (0.52) | CYP2A6KIF11ALDH1A1KDM4EPTGS2 | |
| SCHEMBL30460284 | 0.74 | CYP2A6 (0.52) | CYP2A6KIF11ALDH1A1KDM4EPTGS2 | |
| SCHEMBL25422759 | 0.72 | KIF11 (0.37) | KIF11EGFRALDH1A1KDM4ETDP1 | |
| SCHEMBL806286 | 0.72 | DAO (0.49) | CYP2A6ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31568898 | 0.72 | AHR (0.44) | CYP2A6ALDH1A1 | |
| SCHEMBL15651757 | 0.72 | CYP2A6 (0.58) | CYP2A6KIF11ALDH1A1KDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3512850-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2017205972-A1 | SYSTEMS METHODS AND COMPOSITIONS FOR PREDICTING METASTASIS IN BLADDER CANCER | GENOMEDX BIOSCIENCES, INC. (CA) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885KIF11 1741/4885EGFR 3913/4885 |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885KIF11 1741/4885EGFR 3913/4885 |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885KIF11 1741/4885EGFR 3913/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885KIF11 1741/4885EGFR 3913/4885 |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885KIF11 1741/4885EGFR 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.